
New Zealand approves MDMA for PTSD treatment, second country globally to do so
The story in brief
New Zealand has approved pharmaceutical-grade MDMA for treating severe PTSD, making it the second country globally to do so after Australia. The treatment will combine MDMA with psychotherapy in controlled settings, addressing a mental health condition caused by traumatic events. Clinical trials continue in the U.S., where the FDA rejected MDMA's use in 2024 due to insufficient evidence.